

CHAPTER VI

REFERENCES

- Bishara, J., Pitlik, S., and Samra, Z. (2003). Co-trimoxazole-Sensitive, Methicillin-Resistant Staphylococcus aureus, Israel, 1988-1997. *Emerging Infectious Diseases*, 9(9), pp. 1168-1169.
- Boucher, H. and Corey, G. (2008). Epidemiology of Methicillin-Resistant Staphylococcus aureus. *Clinical Infectious Diseases*, 46(S5), pp.S344-S349.
- Brown, D. (2005). Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). *Journal of Antimicrobial Chemotherapy*, 56(6), pp.1000-1018.
- CDC. (2013). Antibiotic Resistance Threats in the United States”. Centers for Disease Control and Prevention 27. <http://www.cdc.gov/>.
- CLSI. (2015). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute.
- CLSI. (2015). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard: Eleventh Edition. CLSI document M02-A11. Cockerill, Franklin R.: Clinical and Laboratory Standards Institute.
- Datta, P. and Gulati, N. (2011). Evaluation of various methods for the detection of methicillin-resistant Staphylococcus aureus strains and susceptibility patterns. *Journal of Medical Microbiology*, 60(11), pp. 1613-1616.
- Dworkin, M. (2007). *The Prokaryotes 4th Volume*. 3rd ed. New York: Springer.
- Eliopoulos, G. and Huovinen, P. (2001). Resistance to Trimethoprim-Sulfamethoxazole. *Clinical Infectious Diseases*, 32(11), pp. 1608-1614.
- Enright, M. and Randle, G. (2002). The Evolutionary History of Methicillin-resistant Staphylococcus aureus (MRSA). *PNAS* 11. 99, pp. 7687-692.
- Erikawati, D., Santoningsih, D., and Santoso, S. (2016). Tingginya Prevalensi MRSA pada Isolat Klinik Periode 2010-2014 di RSUD Dr. Saiful Anwar Malang, Indonesia. *Jurnal Kedokteran Brawijaya*, 29(2), pp.149-156.
- FDA. Review Criteria for Assessment of Antimicrobial Susceptibility Test Discs. U.S. Department of Health and Human Services Food and Drug Administration (1997).

- Fitzgerald, R., Sturdevant, D., and Mackie, S. (2001). Evolutionary Genomics of Staphylococcus aureus: Insights into the Origin of Methicillin-resistant Strains and the Toxic Shock Syndrome Epidemics. PNAS 15. 98, pp. 8821-826.
- Forcade, N., Parchman, M. and Jorgensen, J. (2011). Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas; A South Texas Ambulatory Research Network (STARNet) Study. The Journal of the American Board of Family Medicine, 24(5), pp.543-550.
- Foster, T. (2005). Immune evasion by staphylococci. Nature Reviews Microbiology, 3(12), pp.948-958.
- Goldberg, E., Paul, M., and Talker, O. (2010). Co-trimoxazole versus vancomycin for the treatment of Methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 65(8), pp. 1779-1783.
- Gosbell, I. (2004). Methicillin-Resistant Staphylococcus aureus. American Journal of Clinical Dermatology, 5(4), pp. 239-259.
- Gould, F., Brindle R. and Chandwick P. (2008). Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. Journal of Antimicrobial Chemotherapy 63, pp. 849-61.
- Jarraud, S., Mougel C. and Thioulouse J. (2002). Relationships between Staphylococcus Aureus Genetic Background, Virulence Factors, Agr Groups (Alleles), and Human Disease. Infection and Immunity 2(70), pp. 631-41.
- Jorgensen, J., Pfaller, M. and Carroll, K. (2015). Manual of clinical microbiology. 11th ed. Washington: ASM Press.
- Lee, B. (2013). The Economic Burden of Community-associated Methicillin-resistant Staphylococcus aureus (CA-MRSA). Clinical Microbiology and Infection, 19(6), pp.528-536.
- Levy, S. (2002). Factors Impacting on the Problem of Antibiotic Resistance. Journal of Antimicrobial Chemotherapy, 49(1), pp. 25-30.
- Li Z, Willke RJ, Pinto LA, et al. (2001). Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial. Pharmacotherapy;21, pp. 263-74.
- Liu, G. (2009). Molecular Pathogenesis of Staphylococcus aureus Infection. Pediatric Research, 65(5 Part 2), pp.71R-77R.

- IDSA. Liu Catherine, and Bayer A. et al. (2011). Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Disease: IDSA guidelines 52.
- Ní Eidhin, D. and Perkins, S. (1998). Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Molecular Microbiology, 30(2), pp.245-257.
- Patti, J., Allen, B., McGavin, M. and Hook, M. (1994). MSCRAMM-Mediated Adherence of Microorganisms to Host Tissues. Annual Review of Microbiology, 48(1), pp.585-617.
- Proctor, R. (2008). Role of Folate Antagonists in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection. Clinical Practice article 46, pp. 584-93.
- Reygaert, W. (2013). Antimicrobial Resistance Mechanisms of Staphylococcus Aureus. Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education (A. Méndez-Vilas, Ed.), pp. 297-305.
- Rosner, A., Becker D., and Wong, A. (2004). The Costs and Consequences of Methicillin-resistant Staphylococcus aureus Infection Treatments in Canada. Can J Infect Dis Med Microbiol 4(15), pp.213-20.
- Schleifer, K. and Bell, J. (2015). Staphylococcus. Bergey's Manual of Systematics of Archaea and Bacteria, pp.1-43.
- Wertheim, H., Melles D., and Vos M. (2005). The Role of Nasal Carriage in Staphylococcus aureus Infection. Lancet Infection Disease 5, pp. 751-62.